ArmonAir Digihaler
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $751,074 | 44 | 0 |
| 2023 | $9,700 | 44 | 25 |
| 2022 | $743.58 | 37 | 36 |
| 2021 | $207,989 | 1,215 | 882 |
| 2020 | $239.10 | 15 | 14 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $751,074 | 44 | 77.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $182,355 | 100 | 18.8% |
| Food and Beverage | $32,972 | 1,189 | 3.4% |
| Travel and Lodging | $3,345 | 22 | 0.3% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Open Label, Active-Controlled, Parallel-Group, Multiple-Dose, Multiple-Site, Patient Use Study to Obtain Partially Used Test Fluticasone Propionate Inhalation Aerosol, 110 mcg (Teva) Devices and Reference FLOVENT HFA (fluticasone propionate inhalation aerosol), 110 mcg (GlaxoSmithKline) Devices, After Repeated Use in Patients with Asthma | Teva Pharmaceuticals USA, Inc. | $726,110 | 0 |
| Use of ProAir Digihaler in COPD - Characterization of inhalation parameters from a cohort of patient at-risk for AECOPD in an outpatient setting | Teva Pharmaceuticals USA, Inc. | $13,225 | 0 |
| ProAir Digihaler in COPD Disease Management: A real world study to assess ProAir Digihaler inhalation parameters thresholds and their use to identify deterioration in clinical practice | Teva Pharmaceuticals USA, Inc. | $11,739 | 0 |
Top Doctors Receiving Payments for ArmonAir Digihaler
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Farmington Hill, MI | $751,074 | 44 |
| , MD | Allergy & Immunology | Forest, VA | $23,363 | 16 |
| , MD | Allergy | Dallas, TX | $11,323 | 6 |
| , M.D | Allergy | Montgomery, AL | $9,500 | 9 |
| , M.D | Internal Medicine | Gardner, MA | $7,800 | 2 |
| , MD | Pulmonary Disease | Westminster, CA | $6,539 | 5 |
| , M.D | Allergy & Immunology | Germantown, TN | $5,840 | 3 |
| , M.D | Allergy & Immunology | Woodland, CA | $5,572 | 4 |
| , M.D | Specialist | Stockton, CA | $5,457 | 5 |
| , M.D | Allergy & Immunology | Pembroke Pines, FL | $5,040 | 3 |
| , M.D | Internal Medicine | Mentor, OH | $4,972 | 4 |
| , M.D | Allergy & Immunology | Powderly, KY | $4,540 | 2 |
| , D.O | Allergy | Lakewood, WA | $4,160 | 2 |
| , MD-PHD | Allergy & Immunology | New York, NY | $3,876 | 3 |
| , MD | Pediatrics | Lafayette, IN | $3,760 | 2 |
| , MD | Allergy & Immunology | Charlotte, NC | $3,707 | 7 |
| , M.D., | Allergy | Bloomingdale, IL | $3,550 | 2 |
| , M.D | Allergy & Immunology | Fredericksburg, VA | $3,540 | 2 |
| , MD | Allergy & Immunology | Pikeville, KY | $3,360 | 2 |
| , MD | Critical Care Medicine | Tracy, CA | $3,125 | 1 |
| , MD | Allergy & Immunology | Belle Mead, NJ | $2,995 | 2 |
| , M.D | Allergy & Immunology | Indianapolis, IN | $2,990 | 4 |
| , M.D | Allergy & Immunology | Saint Louis, MO | $2,940 | 3 |
| , M.D | Allergy & Immunology | Tampa, FL | $2,880 | 1 |
| , PA-C | Physician Assistant | South Easton, MA | $2,616 | 5 |
Manufacturing Companies
- Teva Pharmaceuticals USA, Inc. $969,746
Product Information
- Type Drug
- Total Payments $969,746
- Total Doctors 944
- Transactions 1,355
About ArmonAir Digihaler
ArmonAir Digihaler is a drug associated with $969,746 in payments to 944 healthcare providers, recorded across 1,355 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2020 to 2024. In 2024, $751,074 was paid across 44 transactions to 0 doctors.
The most common payment nature for ArmonAir Digihaler is "Unspecified" ($751,074, 77.5% of total).
ArmonAir Digihaler is associated with 3 research studies, including "A Randomized, Open Label, Active-Controlled, Parallel-Group, Multiple-Dose, Multiple-Site, Patient Use Study to Obtain Partially Used Test Fluticasone Propionate Inhalation Aerosol, 110 mcg (Teva) Devices and Reference FLOVENT HFA (fluticasone propionate inhalation aerosol), 110 mcg (GlaxoSmithKline) Devices, After Repeated Use in Patients with Asthma" ($726,110).